Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Slides:

Advertisements

Similar presentations

Verstovsek S et al. Proc ASCO 2011;Abstract 6500.

Advertisements

Ongoing clinical trials with JAK2 inhibitors in MF

Perspectives on defining ruxolitinib resistance/suboptimal response and therapeutic decision-making in this setting Claire Harrison, MD.

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.

Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.

The Efficacy and Safety of Continued Hydroxyurea Therapy versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind,

Risk Stratification of Patients with Myelofibrosis and the Role of Transplant Alessandro M. Vannucchi Section of Hematology, University of Florence, Italy.

Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.

Case Study: A Woman with Post-PV MF of Long Duration Ruben A. Mesa, MD, FACP Chair, Division of Hematology & Medical Oncology Deputy Director, Mayo Clinic.

Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Volume 60, Issue 5, Pages (November 2011)

Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

CCO Independent Conference Highlights

New Findings in Hematology: Independent Conference Coverage

CCO Independent Conference Highlights

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1

Verstovsek S et al. Proc ASH 2011;Abstract 793.

Harrison CN et al. Proc ASH 2015;Abstract 59.

Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.

Combination Ruxolitinib + Sonidegib in Myelofibrosis

PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.

Volume 60, Pages (September 2017)

New Findings in Hematology: Independent Conference Coverage

Mean Percent Change From Baseline to Week 24 ± SD

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

Whom should you refer for allogeneic stem cell transplantation?

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias Jorge E. Cortes, Carlo Gambacorti-Passerini,

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Novel and Emerging Approaches to Treating CLL

Whom should you refer for allogeneic transplantation?

Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M

Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome–Negative Myeloproliferative Neoplasms Olga Pozdnyakova, Robert.

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab.

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Does Karnofsky Performance Status of Patients With Cirrhosis on the Transplant Waitlist Meet the Eyeball Test? Elliot B. Tapper, MD Clinical Gastroenterology.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Tips on using ruxolitinib

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders Martin Benesch, MD, H. Joachim.

Presentation transcript:

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects Hagop M. Kantarjian, Richard T. Silver, Rami S. Komrokji, Ruben A. Mesa, Roland Tacke, Claire N. Harrison Clinical Lymphoma, Myeloma and Leukemia Volume 13, Issue 6, Pages 638-645 (December 2013) DOI: 10.1016/j.clml.2013.09.006 Copyright © 2013 The Authors Terms and Conditions

Figure 1 Percentage Change in Spleen Volume (A) and Total Symptom Score (B) From Baseline to Week 24, by COMFORT-I Patient Subgroup33 Dashed lines represent the mean percentage change from baseline for overall treatment group.24 Abbreviations: COMFORT = Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; ECOG PS = Eastern Cooperative Oncology Group performance status; Hb = hemoglobin level; Int-2 = Intermediate-2; IPSS = International Prognostic Scoring System; JAK = Janus kinase; MF = myelofibrosis; PET = post-essential thrombocythemia; PMF = primary myelofibrosis; PPV = post-polycythemia vera; SEM = standard error of the mean. (Reprinted with permission from Blackwell Publishing Ltd. Verstovsek S, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol 2013; 161:508-16. © 2013 Blackwell Publishing Ltd.) Clinical Lymphoma, Myeloma and Leukemia 2013 13, 638-645DOI: (10.1016/j.clml.2013.09.006) Copyright © 2013 The Authors Terms and Conditions

Figure 2 Mean Percentage Change From Baseline in (A) Platelet Counts and (B) Hemoglobin Levels Over Time39 The graphs for this figure, originally part of a poster presentation [39], have now been published (Verstovsek, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 2013;6:1-9 [Published by Dove Press]). Clinical Lymphoma, Myeloma and Leukemia 2013 13, 638-645DOI: (10.1016/j.clml.2013.09.006) Copyright © 2013 The Authors Terms and Conditions